Literature DB >> 9663153

Directly observed therapy and treatment completion for tuberculosis in the United States: is universal supervised therapy necessary?

R Bayer1, C Stayton, M Desvarieux, C Healton, S Landesman, W Y Tsai.   

Abstract

OBJECTIVES: This study examined the relationship between directly observed therapy and treatment completion rates in the years before and after infusion of federal funding for tuberculosis (TB) control in 1993.
METHODS: An ecological study of estimated directly observed therapy rates and 12-month treatment completion rates from 1990 through 1994 was undertaken for TB control programs in all 25 cities and counties across the nation with 100 or more incident TB cases in any year from 1990 to 1993. Three cohorts were formed: high treatment completion, intermediate completion, and low completion.
RESULTS: In 1990, the median 12-month treatment completion rate was 80% for the entire study population, with a median estimated directly observed therapy rate of 16.8%. By 1994, those rates had increased to 87% and 49.4%, respectively, and increases were shown in all 3 cohorts.
CONCLUSIONS: Directly observed therapy has had a marked impact on treatment completion rates in jurisdictions with historically low rates. But TB treatment completion rates of more than 90% can be attained with directly observed therapy rates far lower than those proposed by advocates of universal supervised therapy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9663153      PMCID: PMC1508250          DOI: 10.2105/ajph.88.7.1052

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  16 in total

1.  The problem of self-administration of drugs; with particular reference to pulmonary tuberculosis.

Authors:  W FOX
Journal:  Tubercle       Date:  1958-10

2.  Eleven years of community-based directly observed therapy for tuberculosis.

Authors:  C P Chaulk; K Moore-Rice; R Rizzo; R E Chaisson
Journal:  JAMA       Date:  1995-09-27       Impact factor: 56.272

Review 3.  Directly observed therapy for tuberculosis: history of an idea.

Authors:  R Bayer; D Wilkinson
Journal:  Lancet       Date:  1995-06-17       Impact factor: 79.321

4.  Legal advocacy in a time of plague.

Authors:  S L Jacobs
Journal:  J Law Med Ethics       Date:  1993 Fall-Winter       Impact factor: 1.718

5.  'Shoe leather therapy' is gaining on TB.

Authors:  R Voelker
Journal:  JAMA       Date:  1996-03-13       Impact factor: 56.272

6.  Beyond four drugs. Public health policy and the treatment of the individual patient with tuberculosis.

Authors:  E A Nardell
Journal:  Am Rev Respir Dis       Date:  1993-07

7.  The relationship between delayed or incomplete treatment and all-cause mortality in patients with tuberculosis.

Authors:  A Pablos-Méndez; T R Sterling; T R Frieden
Journal:  JAMA       Date:  1996-10-16       Impact factor: 56.272

8.  Tuberculosis in New York City--turning the tide.

Authors:  T R Frieden; P I Fujiwara; R M Washko; M A Hamburg
Journal:  N Engl J Med       Date:  1995-07-27       Impact factor: 91.245

9.  The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis.

Authors:  S E Weis; P C Slocum; F X Blais; B King; M Nunn; G B Matney; E Gomez; B H Foresman
Journal:  N Engl J Med       Date:  1994-04-28       Impact factor: 91.245

Review 10.  The need for epidemic intelligence.

Authors:  A B Bloch; I M Onorato; W W Ihle; J L Hadler; C H Hayden; D E Snider
Journal:  Public Health Rep       Date:  1996 Jan-Feb       Impact factor: 2.792

View more
  12 in total

Review 1.  Directly observed therapy (DOT) for tuberculosis: why, when, how and if?

Authors:  L P Ormerod
Journal:  Thorax       Date:  1999-08       Impact factor: 9.139

2.  A novel approach to directly observed therapy for tuberculosis in an HIV-endemic area.

Authors:  M Desvarieux; P R Hyppolite; W D Johnson; J W Pape
Journal:  Am J Public Health       Date:  2001-01       Impact factor: 9.308

3.  Directly observed therapy and tuberculosis treatment completion. Jereb et al. re: Bayer et al.

Authors:  J A Jereb; P M Simone; I M Onorato
Journal:  Am J Public Health       Date:  1999-04       Impact factor: 9.308

4.  Directly observed therapy and tuberculosis treatment completion. Novick and Lipsman re: Bayer et al.

Authors:  L F Novick; J Lipsman
Journal:  Am J Public Health       Date:  1999-04       Impact factor: 9.308

5.  Directly observed therapy and tuberculosis treatment completion. Bloch re: Bayer et al.

Authors:  A B Bloch
Journal:  Am J Public Health       Date:  1999-04       Impact factor: 9.308

6.  Directly observed therapy and tuberculosis treatment completion. Frieden re: Bayer et al.

Authors:  T R Frieden
Journal:  Am J Public Health       Date:  1999-04       Impact factor: 9.308

7.  Nihilism and pragmatism in tuberculosis control.

Authors:  P Farmer; E Nardell
Journal:  Am J Public Health       Date:  1998-07       Impact factor: 9.308

8.  What it takes to control tuberculosis.

Authors:  C R Horsburgh
Journal:  Am J Public Health       Date:  1998-07       Impact factor: 9.308

Review 9.  Treatment and prevention of multidrug-resistant tuberculosis.

Authors:  I Bastian; R Colebunders
Journal:  Drugs       Date:  1999-10       Impact factor: 9.546

10.  Public health nihilism vs pragmatism: history, politics, and the control of tuberculosis.

Authors:  A L Fairchild; G M Oppenheimer
Journal:  Am J Public Health       Date:  1998-07       Impact factor: 9.308

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.